Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16440503 | 0.81 | MAPK1 (0.37) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL45873 | 0.79 | MAPK1 (0.36) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL10211764 | 0.78 | CYP2C19 (0.45) | MAPK1KMT2AYEATS4RAB9A | |
| SCHEMBL13252961 | 0.78 | MAPK1 (0.33) | MAPK1KMT2AYEATS4 | |
| SCHEMBL1522621 | 0.77 | YEATS4 (0.37) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL9829813 | 0.77 | MAPK1 (0.35) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL14241961 | 0.77 | MAPK1 (0.35) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL2694202 | 0.77 | CYP2E1 (0.45) | MAPK1KMT2A | |
| SCHEMBL10211605 | 0.77 | KMT2A (0.47) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL18349188 | 0.77 | KMT2A (0.44) | MAPK1KMT2AYEATS4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230225184-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-07-13 | — | — | US | disclosed |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180159052-A1 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | NEXT ENERGY TECHNOLOGIES, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9867811-B2 | Method of treating atherosclerosis in high triglyceride subjects | NOVARTIS AG (CH) | 2018-01-16 | — | — | US | disclosed |
| US-9865821-B2 | Organic semiconducting compounds for use in organic electronic devices | NEXT ENERGY TECHNOLOGIES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-9744147-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM DERMALOGIX, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2016-11-17 | — | — | US | disclosed |
| US-9376383-B2 | Isoprenyl compounds | SIGNUM BIOSCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20160020413-A1 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | NEXT ENERGY TECHNOLOGIES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150034161-A1 | ORGANIC SEMICONDUCTING COMPOUNDS FOR USE IN ORGANIC ELECTRONIC DEVICES | NEXT ENERGY TECHNOLOGIES, INC. | 2015-02-05 | — | — | US | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | SIGNUM BIOSCIENCES, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-8372884-B2 | Isoprenyl compounds and methods thereof | SIGNUM BIOSCIENCES, INC. | 2013-02-12 | — | — | US | disclosed |
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-08-16 | — | — | US | disclosed |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | SIGNUM BIOSCIENCES, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208819-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885KMT2A 1654/4885YEATS4 1625/4885 |
| US-20230225184-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ESRRG, TECR, OXSR1 | MAPK1 631/4885KMT2A 3601/4885YEATS4 1866/4885 |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | MAPK1 3652/4885KMT2A 3036/4885YEATS4 1266/4885 |
| US-20180159052-A1 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | SLC43A1, SLC7A5, EPCAM | MAPK1 3779/4885KMT2A 1058/4885YEATS4 373/4885 |
| US-20150034161-A1 | ORGANIC SEMICONDUCTING COMPOUNDS FOR USE IN ORGANIC ELECTRONIC DEVICES | OR10J3, EPCAM, TRPA1 | MAPK1 4189/4885KMT2A 2105/4885YEATS4 610/4885 |
| US-20160361283-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | MAPK1 3315/4885KMT2A 4130/4885YEATS4 2816/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | MAPK1 3346/4885KMT2A 3013/4885YEATS4 1099/4885 |
| US-20100184768-A1 | Isoprenyl Compounds and Methods Thereof | ALOX15B, ALOX15, ALOX5 | MAPK1 3315/4885KMT2A 4130/4885YEATS4 2816/4885 |
| US-10314802-B2 | Isoprenyl compounds and methods thereof | ALOX15B, ALOX15, ALOX5 | MAPK1 3315/4885KMT2A 4130/4885YEATS4 2816/4885 |
| US-20130310559-A1 | ISOPRENYL COMPOUNDS AND METHODS THEREOF | ALOX15B, ALOX15, ALOX5 | MAPK1 3315/4885KMT2A 4130/4885YEATS4 2816/4885 |
| US-10030016-B2 | Heterocyclic compounds useful as PDK1 inhibitors | PDK1, PDK2, PDK3 | MAPK1 382/4885KMT2A 1654/4885YEATS4 1625/4885 |
| US-20160331756-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | MAPK1 382/4885KMT2A 1654/4885YEATS4 1625/4885 |
| US-20160020413-A1 | ELECTRONIC DEVICES USING ORGANIC SMALL MOLECULE SEMICONDUCTING COMPOUNDS | SLC43A1, SLC7A5, EPCAM | MAPK1 3779/4885KMT2A 1058/4885YEATS4 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.